Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2018
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities involving the exchange of common stock for newly designated Series B Convertible Preferred Stock.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a capital structure transaction.
- Transaction Volume: Exchange of 1,000,000 shares of Common Stock for 1,000 shares of Series B Convertible Preferred Stock.
- Counterparty: Biotechnology Value Fund (BVF) entities.
- Ownership Context: As of the agreement date, BVF beneficially owned 1,726,590 shares of Common Stock (approximately 9.49% of outstanding shares) and 2,220 shares of Series A Preferred Stock (convertible into 2,220,000 shares of Common Stock).
Material Changes Versus Prior Period
The filing details a specific corporate action rather than a period-over-period financial comparison. The material change is the creation of a new class of equity:
- New Security Designation: On November 16, 2018, the Company designated 1,000 shares of authorized preferred stock as Series B Convertible Preferred Stock.
- Conversion Terms: Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock.
- Ownership Blocker: Conversion is subject to a 9.99% beneficial ownership blocker provision, preventing the holder from converting if it would cause them to own more than 9.99% of the total outstanding Common Stock.
Guidance, Outlook, and Material Terms
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding business operations. It outlines the legal and structural terms of the new preferred stock:
- Liquidation Preference: Holders receive $0.001 per share before Common Stock holders and on parity with Series A Preferred Stock holders.
- Voting Rights: Generally no voting rights, except as required by law or to amend the terms of the Series B Preferred Stock.
- Dividends: Entitled to receive any dividends payable to Common Stock holders.
- Closing Date: The exchange was expected to close on or around November 19, 2018.
- Regulatory Status: Issued in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the exchange (expected November 19, 2018) and confirm the issuance of the 1,000 Series B shares.
- Review the full text of the Certificate of Designation (Exhibit 3.1) to understand specific adjustment mechanisms for the conversion ratio.
- Confirm the current beneficial ownership percentage of BVF to ensure the 9.99% blocker provision is accurately calculated against the most recent share count.
- Check subsequent filings for any amendments to the Series B terms or additional exchanges with BVF.